TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23053683
Drug: Adalimumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (20 mg every other week for patients <30 kg; 40 mg every other week for patients ≥30 kg) with concomitant methotrexate allowed (≤10 mg/m² per week)
Study: 23054206
Drug: TRC102 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC102 at 15, 30, 60 or 100 mg/m(2)/d
Study: 23054206
Drug: TRC102 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC102 combined with standard-dose pemetrexed
Study: 23054206
Drug: TRC102 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC102 at 60 mg/m(2)/d for 4 days with pemetrexed
Study: 23054208
Drug: Foretinib 80
Normalized name: Foretinib
DrugBank: Foretinib (DB12307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foretinib 80 mg once daily
Study: 23054338
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (OV)
Study: 23056238
Drug: BSAM2/Alhydrogel®+CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSAM2/Alhydrogel®+CPG 7909 (40 µg total protein)
Study: 23056238
Drug: BSAM2/Alhydrogel®+CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSAM2/Alhydrogel®+CPG 7909 (160 µg total protein)
Study: 23056238
Drug: BSAM2/Alhydrogel®+CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSAM2/Alhydrogel®+CPG 7909 (both doses)
Study: 23056467
Drug: External counterpulsation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External counterpulsation therapy (ECP) at high inflation pressure (300 mmHg)
Study: 23056467
Drug: External counterpulsation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External counterpulsation therapy (ECP) at low inflation pressure (80 mmHg)
Study: 23057791
Drug: Flibanserin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin (50 or 100 mg once daily at bedtime or 25 or 50 mg twice daily)
Study: 23057791
Drug: Flibanserin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin (100 mg qhs for ≥180 days)
Study: 29649953
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy
Study: 23059454
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM; acupuncture and herbs)
Study: 23059643
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg twice per day for 3 weeks, increased to 1 g twice per day at week 3 for 3 weeks, then titrated to 2 g twice per day at week 6 for 3 weeks)
Study: 23063302
Drug: Intradermally injected
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermally injected botulinum neurotoxin type A (BoNT/A), 20 intradermal injections of 0.05 ml in symptomatic areas of lower limbs.
Study: 23064954
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg plus gemcitabine 1,250 mg/m(2)
Study: 23065325
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration in women
Study: 23065325
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration in men
Study: 23065514
Drug: Nilotinib or
Normalized name: nilotinib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib or Dasatinib treatment (exact dosage and duration not specified)
Study: 23065514
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both groups
Study: 23065525
Drug: Plitidepsin 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 3.2 mg/m(2) administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks
Study: 23065953
Drug: Vinblastine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine and celecoxib (metronomic therapy)
Study: 23065953
Drug: Standard multiagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multiagent chemotherapy (ifosfamide-etoposide, vincristine, doxorubicin, cyclophosphamide)
Study: 23067033
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (330-660 mg iron sulphate tablets daily for 2 months)
Study: 23071222
Drug: Lexatumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lexatumumab (10 mg/kg, administered once every 2 weeks)
Study: 23072496
Drug: Amlodipine/Olmesartan Medoxomil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Olmesartan Medoxomil (AML/OM) 5/20 mg, uptitrated to 5/40 mg, 10/40 mg, 10/40 mg + HCTZ 12.5 mg, and 10/40 mg + HCTZ 25 mg
Study: 23073953
Drug: Chloride-restrictive intravenous
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloride-restrictive intravenous fluid strategy (lactated solution, balanced solution, chloride-poor 20% albumin)
Study: 23073953
Drug: Chloride-liberal intravenous
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloride-liberal intravenous fluid strategy (standard intravenous fluids including chloride-rich solutions)
Study: 23077008
Drug: MEK inhibitor
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK inhibitor treatment
Study: 23077109
Drug: m-FLAI regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-FLAI regimen (fludarabine 25 mg/m² days 1-4, cytarabine 1,000 mg/m² days 1-4, idarubicin 5 mg/m² days 1-3)
Study: 23077849
Drug: DTaP-IPV//PRP-T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV//PRP-T vaccine
Study: 23077849
Drug: DTaP-IPV vaccine
Normalized name: DTaP-IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV vaccine (second booster)
Study: 23078588
Drug: Rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10 mg (for patients ≥40 kg)
Study: 23078588
Drug: Rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5 mg (for patients <40 kg)
Study: 23078786
Drug: autologous (auto)-allogeneic
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous (auto)-allogeneic (allo) tandem stem cell transplantation (SCT) with melphalan 200 mg/m(2) followed by melphalan 140 mg/m(2) and fludarabine 180 mg/m(2)
Study: 23078909
Drug: Vidofludimus 35mg
Normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidofludimus 35mg once daily for 12 weeks
Study: 23080404
Drug: 100-Hz Magnetic
Normalized name: Magnesia
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-Hz Magnetic Seizure Therapy (MST), up to 18 treatment sessions
Study: 23080404
Drug: 100-Hz Magnetic
Normalized name: Magnesia
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-Hz Magnetic Seizure Therapy (MST)
Study: 23083061
Drug: TPF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF chemotherapy (docetaxel 30 mg/m2, cisplatin 40 mg/m2, fluorouracil 2000 mg/m2)
Study: 23083774
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg in LBW patients
Study: 23083774
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg in HBW patients
Study: 23083774
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg in LBW patients
Study: 23085463
Drug: Lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 5 mg for four cycles (day 100-180 after allograft)
Study: 23087179
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg subcutaneously monthly for 6 months
Study: 23092052
Drug: Darunavir/ritonavir-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir-based therapy (600 mg darunavir and 100 mg ritonavir twice daily)
Study: 23092052
Drug: Darunavir/ritonavir-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir-based therapy
Study: 23092873
Drug: Cytarabine 2
Normalized name: cytarabine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine 2 g/m(2) over 72 hours (667 mg/m(2)/24 hours) + SCH 900776 10 mg/m(2)/dose
Study: 23094954
Drug: Inhaled route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled route of application
Study: 23094954
Drug: Sublingual route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual route of application
Study: 23094954
Drug: Intranasal route
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal route of application
Study: 23094954
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route of application
Study: 23095978
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of recombinant human IGF-I/IGFBP-3; dosage between 21 and 111 µg/kg/24 h, median duration of 168 hours (range 47-168 hours).
Study: 23096768
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) and radiation (RT) + modified infusional 5-FU, folinic acid, and oxaliplatin chemotherapy (mFOLFOX-6)
Study: 23098130
Drug: Established blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established blood tests (e.g. White Blood Count, Neutrophils, C-reactive protein)
Study: 23098625
Drug: PR-104 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-104 combined with gemcitabine 800 mg/m2
Study: 23098625
Drug: PR-104 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-104 combined with docetaxel 60 mg/m2
Study: 23098625
Drug: PR-104 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-104 combined with docetaxel 60 mg/m2 plus G-CSF
Study: 23098625
Drug: PR-104 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-104 combined with docetaxel 75 mg/m2 plus G-CSF
Study: 23098625
Drug: PR-104 pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-104 pharmacokinetics
Study: 23098625
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose for phase II trials
Study: 23099009
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (220 mg/m² twice a day for children and 400 mg twice a day for adults) for 6 months
Study: 23099849
Drug: Genotypic resistance-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic resistance-guided sequential therapy (esomeprazole and amoxicillin for 7 days, followed by esomeprazole and metronidazole plus clarithromycin, levofloxacin or tetracycline for another 7 days)
Study: 23099849
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with clarithromycin
Study: 23099849
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with levofloxacin
Study: 23099849
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with tetracycline
Study: 23100308
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of α-galactosylceramide-loaded monocyte-derived dendritic cells and low-dose lenalidomide
Study: 23102735
Drug: Inhaled endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled endotoxin
Study: 23106988
Drug: Robotic-guided three-dimensional
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-guided three-dimensional repetitive motion training (15-20 daily sessions of 25-30 min each over 4-8 weeks)
Study: 23109692
Drug: Bendamustine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine at 120 mg/m(2) per day on days 1 through 2 every 3 weeks for six cycles
Study: 23109699
Drug: Final PET
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final PET at the end of treatment (n = 106)
Study: 23111057
Drug: 5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg/kg human recombinant granulocyte colony-stimulating factor (hrG-CSF)
Study: 23112822
Drug: MDMA (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.4 mg/kg, range 75-100 mg)
Study: 23113026
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EPA and Vitamin E
Study: 23113909
Drug: Cholesterol-reducing treatment
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-reducing treatment decision making
Study: 23113909
Drug: Communication about
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication about treatment options
Study: 23114372
Drug: Vaccine-naive group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-naive group
Study: 23114473
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment modalities
Study: 23115344
Drug: Treatment adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adherence (assessed using the Heart Failure Compliance Questionnaire)
Study: 23116538
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) - Privigen®, dose 0.4 gram/kg, for 6 months
Study: 23118116
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 1000 mg infusion at months 0 and 6 with 100 mg methylprednisolone
Study: 23118984
Drug: MVA-NP+M1 vaccine
Normalized name: Ceramide Np
DrugBank: Ceramide NP (DB14111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-NP+M1 vaccine (1.5×10^8 pfu)
Study: 23122784
Drug: Lapatinib (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1250 mg, orally daily) plus capecitabine (2000 mg/m², orally from day 1 to day 14)
Study: 23124321
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg) administered on days 1 and 15
Study: 23130134
Drug: n3-PUFAs 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: n3-PUFAs 2 g orally twice daily (minimum of 6 g)
Study: 23130135
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg/d with high on-aspirin RPR and low von Willebrand factor
Study: 23130135
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg/d with high on-aspirin RPR and low platelet count
Study: 23131206
Drug: 6 μg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 μg PhtD vaccine candidate
Study: 23131206
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg PhtD vaccine candidate
Study: 23131206
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg PhtD vaccine candidate
Study: 23131206
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose levels of PhtD vaccine candidate
Study: 23134762
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral cholecalciferol (vitamin D3)
Study: 23137499
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of 1 × 10(5)/kg or 5 × 10(5)/kg CD34(+) cells
Study: 23137499
Drug: G-CSF-mediated stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF-mediated stem cell mobilization
Study: 23138731
Drug: Drug-resistant virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-resistant virus
Study: 23140536
Drug: Rapamycin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin (target plasma levels between 4 and 8 ng/ml)
Study: 23142061
Drug: TMC435 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 monotherapy (200 mg once daily for 7 days)
Study: 23143411
Drug: Quetiapine extended
Normalized name: Quetiapine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine extended release (XR), 150-300 mg/day
Study: 23143939
Drug: Intranasal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketorolac tromethamine 31.5 mg (15.75 mg per nostril)
Study: 23144193
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg by mouth once daily on days 1-28 of a 28-day cycle with rituximab administered weekly during cycle one and then on day one of subsequent cycles
Study: 23144193
Drug: Everolimus in
Normalized name: Product containing everolimus in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus in combination with rituximab
Study: 23144200
Drug: Melphalan, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan, lenalidomide, and dexamethasone; melphalan 5 mg/m²/day for 4 days, lenalidomide 10 mg/day for 21 days, dexamethasone 20-40 mg once a week every 28 days for 12 cycles.
Study: 23145537
Drug: Zinc sulfate,
Normalized name: Zinc sulfate, anhydrous
DrugBank: Zinc sulfate (DB09322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc sulfate, 220 mg per capsule, two capsules per day for three months
Study: 23145922
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention by pharmacists and other healthcare professionals
Study: 23146956
Drug: Lapatinib 1250mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1250mg/day and Sorafenib 400mg twice daily (RPTD)
Study: 23146956
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and Sorafenib combination treatment
Study: 23147218
Drug: ABT-751 125
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-751 125 mg orally twice daily for 7 days with carboplatin AUC 6
Study: 23148516
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine delivery excluding vaccine costs
Study: 23148516
Drug: Financial scaled-up
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial scaled-up costs excluding vaccine and salaries
Study: 23148799
Drug: Sumatriptan auto-injector
Normalized name: sumatriptan Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan auto-injector (6 mg subcutaneous)
Study: 23151076
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord mesenchymal stem cells (UCMSCs) therapy
Study: 23151237
Drug: Self-Administered Comorbidity
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Administered Comorbidity Questionnaire (SCQ)
Study: 23151373
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with deferasirox (DFX, 20-30 mg/kg daily) and deferoxamine (DFO, 35-50 mg/kg on 3-7 days/week)
Study: 23151395
Drug: 12-week non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week non-surgical treatment programme (patient education, exercise, diet, insoles, paracetamol and/or NSAIDs)
Study: 23151395
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (two information leaflets on KOA and advice regarding non-surgical treatment)
Study: 23151395
Drug: 12-week non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week non-surgical treatment programme
Study: 23152364
Drug: Biodegradable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable polymer drug eluting stents (BP-DES)
Study: 23152364
Drug: Durable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durable polymer drug eluting stents (DP-DES)
Study: 23153506
Drug: Doxorubicin-loaded anti-EGFR
Normalized name: Anti-egfr/c-met bispecific antibody emb-01
DrugBank: EMB-01 (DB16091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR ILs-dox) at doses of 5 mg/m(2), 10 mg/m(2), 20 mg/m(2), 30 mg/m(2), 40 mg/m(2), 50 mg/m(2), and 60 mg/m(2) intravenously infused once every 4 weeks for a maximum of six cycles
Study: 23157720
Drug: PEGylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEGylated interferon (PEG-IFN) α-2a or PEG-INF α-2b combined with daily ribavirin (1000-1200 mg/day) for 48 weeks
Study: 23160468
Drug: Low-dose donor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose donor lymphocyte infusions beginning 5 months after transplantation
Study: 23161291
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors post-endoscopy
Study: 23161291
Drug: Aspirin, non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, non-steroidal anti-inflammatory drugs, or warfarin at baseline
Study: 23161291
Drug: Transfusions other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusions other than intravenous fluid or red blood cells within 12 hours of presentation
Study: 23164174
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (1-10 fractions, total doses of 8-30 Gy)